TrialGut2023
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
N Jewel Samadder et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this papercites it